ClinConnect ClinConnect Logo
Search / Trial NCT04955795

Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jun 30, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Hiv Outcomes Unhealthy Alcohol Use Mental Health Medication Adherence

ClinConnect Summary

This clinical trial is looking at how effective a combination of two types of treatments can be for individuals living with HIV who have unhealthy alcohol use. Specifically, the study will compare a brief intervention, which is a quick counseling session, with a more in-depth cognitive-behavioral therapy (CBT) session. The goal is to see if the extra support from CBT can help improve both alcohol use and mental health symptoms, ultimately leading to better health outcomes for people living with HIV in Alabama.

To participate in this trial, you need to be at least 18 years old, be living with HIV, and be receiving care at one of the participating clinics in Alabama. You should also have a score on the AUDIT survey that indicates unhealthy alcohol use. Participants can expect to engage in telemedicine sessions, which means you will receive treatment through video calls or phone calls from the comfort of your home. It’s important to note that if you have certain conditions, like serious mental health issues or difficulty using a mobile phone, you may not be eligible for this trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years of age or older
  • Living with HIV infection
  • Receiving HIV care at 1 of 4 participating AQMG sites (Alabama Quality Management Group sites - i.e. Ryan White HIV/AIDS Program-funded community clinics in Alabama)
  • Unhealthy alcohol use documented on the AUDIT survey delivered via PRO (i.e. 4 or greater points for women and greater than 8 points for men).
  • Exclusion Criteria:
  • Inability to use a mobile phone due to cognitive or physical impairments
  • Unable to speak sufficient English to provide informed consent and receive cognitive behavioral therapy
  • Active suicidality or psychosis
  • Risk for acute alcohol withdrawal or seizures

About University Of Alabama At Birmingham

The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.

Locations

Huntsville, Alabama, United States

Anniston, Alabama, United States

Montgomery, Alabama, United States

Opelika, Alabama, United States

Anniston, Alabama, United States

Birmingham, Alabama, United States

Huntsville, Alabama, United States

Montgomery, Alabama, United States

Opelika, Alabama, United States

Patients applied

0 patients applied

Trial Officials

Karen Cropsey, Psy.D.

Principal Investigator

University of Alabama at Birmingham

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials